Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Muscle-invasive Urothelial Cancer of the Bladder 1

Interventions

pembrolizumab 304Carboplatin 155Nivolumab 155Cisplatin 140Cyclophosphamide 132Paclitaxel 128Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 91Gemcitabine 87Dexamethasone 85Biopsy 81Ipilimumab 78Doxorubicin 76Docetaxel 75Rituximab 70Etoposide 67atezolizumab 62durvalumab 61Radiation 60Lenalidomide 59Pemetrexed 58Taxes 57Bevacizumab 55Prednisone 55fludarabine 54olaparib 54Vincristine 50Cytarabine 48Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Transurethral Resection of Bladder × 1 year × Clear all
NCT02621151 2025-10-07

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

NYU Langone Health

Phase 2 Active not recruiting
60 enrolled 11 charts
Genitourinary

Muscle-invasive Urothelial Cancer of the Bladder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡